Audience: Participating Otolaryngologists
Excellus BlueCross BlueShield works to ensure that the development of corporate medical policies occurs through an open, collaborative process. We encourage participating providers to become actively involved in medical policy development. Each month, draft policies are available for review and comment. Providers can attach supporting documentation related to their comments.
The following updated medical policy has been reviewed and was approved on May 19, 2022, by the Corporate Medical Policy Committee, including practitioner representatives from all Health Plan regions.
Corporate Medical Policy 7.01.99 – Drug-Eluting Sinus Stents for Post-operative use following Endoscopic Sinus Surgery has been updated to be consistent with the current evidence regarding the use of drug-eluting sinus stents and absorbable nasal implants. The policy name has been changed to Drug-Eluting Sinus Stents and Nasal Implants. This updated policy is effective September 15, 2022. The policy applies to all lines of business and to the services of all practitioners and facilities.
The Drug-Eluting Sinus Stents and Nasal Implants policy provides updates to the criteria for the following indications:
Absorbable Nasal Implants
The rationale section of the medical policy provides information related to the Health Plan’s change in coverage criteria based on the current body of literature regarding drug-eluting sinus stents and nasal implants.
These services are subject to audit and policy updates at the Health Plan’s discretion. You can access the individual policies on the Medical Policies page.
If you have any questions regarding this policy, please contact your Provider Relations representative.
Thank you for the quality of care and service that you provide to our members.